Alvan Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alvan Cai has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Jiang Wu
Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA 94720, United States
1 shared publication- John K. Cusick
Department of Basic Science, California Northstate University College of Medicine
1 shared publication - Lily S. Wang
University of California, Berkeley, CA 94720, USA
1 shared publication Natalie Gonzalez
Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA 94720, United States
1 shared publicationRuoyi Yin
Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA 94720, United States
1 shared publication- Shuo Chen
Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, CA 94720, USA
1 shared publication
Latest Publications
- Open Access
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
HER2 (human epidermal growth factor receptor 2) is highly expressed in a variety of cancers, including breast, lung, gastric, and pancreatic cancers. Its amplification is linked to poor clinical outcomes. At the genetic level, HER2 is encoded by the ERBB2 gene (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), which is frequently mutated or amplified in cancers, thus spurring extensive research into HER2 modulation and inhibition as viable anti-cancer strategies. An impressive body of FDA-approved drugs, including anti-HER2 monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), and HER2-tyrosine kinase inhibitors (TKIs), have demonstrated success in enhancing overall survival (OS) and disease progression-free survival (PFS). Yet, drug resistance remains a persistent challenge and raises the risks of metastatic potential and tumor relapse. Research into alternative therapeutic options for HER2+ breast cancer therefore proves critical for adapting to this ever-evolving landscape. This review highlights current HER2-targeted therapies, discusses predictive biomarkers for drug resistance, and introduces promising emergent therapies—especially combination therapies—that are aimed at overcoming drug resistance in the context of HER2+ breast cancer.
Open AccessDepicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
HER2 (human epidermal growth factor receptor 2) is highly expressed in a variety of cancers, including breast, lung, gastric, and pancreatic cancers. Its amplification is linked to poor clinical outcomes. At the genetic level, HER2 is encoded by the ERBB2 gene (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), which is frequently mutated or amplified in cancers, thus spurring extensive research into HER2 modulation and inhibition as viable anti-cancer strategies. An impressive body of FDA-approved drugs, including anti-HER2 monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), and HER2-tyrosine kinase inhibitors (TKIs), have demonstrated success in enhancing overall survival (OS) and disease progression-free survival (PFS). Yet, drug resistance remains a persistent challenge and raises the risks of metastatic potential and tumor relapse. Research into alternative therapeutic options for HER2+ breast cancer therefore proves critical for adapting to this ever-evolving landscape. This review highlights current HER2-targeted therapies, discusses predictive biomarkers for drug resistance, and introduces promising emergent therapies—especially combination therapies—that are aimed at overcoming drug resistance in the context of HER2+ breast cancer.
- 1 March 2020
- Published by Elsevier in Neuroscience Research
- Vol. 152, 59-65
Towards minimally invasive deep brain stimulation and imaging: A near-infrared upconversion approach
- 1 March 2020
- Published by Elsevier in Neuroscience Research
- Vol. 152, 59-65
Towards minimally invasive deep brain stimulation and imaging: A near-infrared upconversion approach